La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product to treat conditions characterized by iron overload, including hereditary hemochromatosis, beta thalassemia, sickle cell disease, myelodysplastic syndrome, and polycythemia vera. The company was founded in 1989 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-207-4264
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.06 million
Profitability
Miscellaneous
Employees169
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions
What is La Jolla Pharmaceutical's stock symbol?
La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."
How were La Jolla Pharmaceutical's earnings last quarter?
La Jolla Pharmaceutical (NASDAQ:LJPC) issued its quarterly earnings data on Monday, May, 6th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.31) by $0.14. The biopharmaceutical company earned $4.40 million during the quarter, compared to analysts' expectations of $4.98 million. La Jolla Pharmaceutical had a negative return on equity of 337.55% and a negative net margin of 1,324.04%. View La Jolla Pharmaceutical's Earnings History.
When is La Jolla Pharmaceutical's next earnings date?
What guidance has La Jolla Pharmaceutical issued on next quarter's earnings?
La Jolla Pharmaceutical issued an update on its FY 2019 earnings guidance on Monday, March, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $24-28 million, compared to the consensus revenue estimate of $40.28 million.
What price target have analysts set for LJPC?
6 analysts have issued 1 year target prices for La Jolla Pharmaceutical's stock. Their forecasts range from $6.00 to $115.00. On average, they anticipate La Jolla Pharmaceutical's share price to reach $35.20 in the next year. This suggests a possible upside of 540.0% from the stock's current price. View Analyst Price Targets for La Jolla Pharmaceutical.
What is the consensus analysts' recommendation for La Jolla Pharmaceutical?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for La Jolla Pharmaceutical.
What are Wall Street analysts saying about La Jolla Pharmaceutical stock?
Here are some recent quotes from research analysts about La Jolla Pharmaceutical stock:
- 1. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (5/14/2019)
- 2. HC Wainwright analysts commented, "We base our $26 price target on a sum-of-the-parts analysis based on: (1) the P/E value of La Jolla’s current commercial business (Giapreza); (2) an NPV of its pipeline (LJPC-401); and (3) our estimated year-end 2019 fully diluted net cash of $1.69/share to arrive at our price target. We value the current commercial business at $8.76 per share and the pipeline at $15.68 per share. The commercial business value is based on a P/E multiple assumption of 30x our 2024E EPS of $0.51, discounted at 15%." (4/24/2019)
Has La Jolla Pharmaceutical been receiving favorable news coverage?
Media stories about LJPC stock have trended positive on Saturday, InfoTrie reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. La Jolla Pharmaceutical earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are some of La Jolla Pharmaceutical's key competitors?
Some companies that are related to La Jolla Pharmaceutical include Adverum Biotechnologies (ADVM), Heska (HSKA), DBV TECHNOLOGIE/S (DBVT), Scholar Rock (SRRK), Acorda Therapeutics (ACOR), Mesoblast (MESO), Replimune Group (REPL), Krystal Biotech (KRYS), Translate Bio (TBIO), Adaptimmune Therapeutics (ADAP), Agenus (AGEN), Avrobio (AVRO), Gritstone Oncology (GRTS), BioCryst Pharmaceuticals (BCRX) and PDL BioPharma (PDLI).
What other stocks do shareholders of La Jolla Pharmaceutical own?
Who are La Jolla Pharmaceutical's key executives?
La Jolla Pharmaceutical's management team includes the folowing people:
- Dr. George F. Tidmarsh, Pres, CEO, Sec. & Director (Age 59)
- Mr. Dennis M. Mulroy, Chief Financial Officer (Age 64)
- Ms. Jennifer A. Carver, Chief Operating Officer (Age 65)
- Mr. James M. Rolke, Chief Scientific Officer (Age 50)
- Dr. Lakhmir S. Chawla, Chief Medical Officer (Age 48)
Who are La Jolla Pharmaceutical's major shareholders?
La Jolla Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (18.23%), FMR LLC (14.99%), Broadfin Capital LLC (7.36%), BlackRock Inc. (5.33%), Morgan Stanley (1.54%) and Fosun International Ltd (1.54%). Company insiders that own La Jolla Pharmaceutical stock include George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Laura L Douglass, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for La Jolla Pharmaceutical.
Which major investors are selling La Jolla Pharmaceutical stock?
LJPC stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., BlackRock Inc., Northern Trust Corp, Charles Schwab Investment Management Inc., JPMorgan Chase & Co. and Trexquant Investment LP. View Insider Buying and Selling for La Jolla Pharmaceutical.
Which major investors are buying La Jolla Pharmaceutical stock?
LJPC stock was purchased by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Marshall Wace North America L.P., Morgan Stanley, Spark Investment Management LLC, Tang Kevin C, FMR LLC, Fosun International Ltd and Marshall Wace LLP. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for La Jolla Pharmaceutical.
How do I buy shares of La Jolla Pharmaceutical?
Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is La Jolla Pharmaceutical's stock price today?
One share of LJPC stock can currently be purchased for approximately $5.50.
How big of a company is La Jolla Pharmaceutical?
La Jolla Pharmaceutical has a market capitalization of $149.04 million and generates $10.06 million in revenue each year. The biopharmaceutical company earns $-199,470,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. La Jolla Pharmaceutical employs 169 workers across the globe.
What is La Jolla Pharmaceutical's official website?
How can I contact La Jolla Pharmaceutical?
La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]
MarketBeat Community Rating for La Jolla Pharmaceutical (NASDAQ LJPC)
MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical and other stocks. Vote "Outperform" if you believe LJPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LJPC will underperform the S&P 500 over the long term. You may vote once every thirty days.
